Elsa Bernard

Elsa Bernard

Auto-generated profile, based on publicly available information

Elsa Bernard

Inserm U981, Gustave Roussy, Université Paris-Saclay, Villejuif, France

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2020 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
KBKelly L. Bolton
Kelly L. Bolton
RPRyan N. Ptashkin
Ryan N. Ptashkin
TGTeng Gao
Teng Gao
LBLior Braunstein
Lior Braunstein
SDSean M. Devlin
Sean M. Devlin
EPElli Papaemmanuil
Elli Papaemmanuil

3 August 2020 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
EBElsa Bernard
Elsa Bernard
YNYasuhito Nannya
Yasuhito Nannya
RHRobert P. Hasserjian
Robert P. Hasserjian
SDSean M. Devlin
Sean M. Devlin
HTHeinz Tuechler
Heinz Tuechler
EPElli Papaemmanuil
Elli Papaemmanuil

28 March 2024 in Cell
Verified
Journal Article
Closed access
CSCharles Swanton
Charles Swanton
EBElsa Bernard
Elsa Bernard
CAChris Abbosh
Chris Abbosh
FAFabrice André
Fabrice André
JAJohan Auwerx
Johan Auwerx
DHDouglas Hanahan
Douglas Hanahan

8 August 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
YTYanis Tazi
Yanis Tazi
JAJuan E. Arango-Ossa
Juan E. Arango-Ossa
YZYangyu Zhou
Yangyu Zhou
EBElsa Bernard
Elsa Bernard
ITIan Thomas
Ian Thomas
EPElli Papaemmanuil
Elli Papaemmanuil
Clinical recommendations for Acute Myeloid Leukemia (AML) classification and risk-stratification remain heavily reliant on cytogenetic findings at diagnosis, which are present in <50% of patients. Using comprehensive molecular profiling data from 3,653 patients we characterize and validate 16 molecular classes describing 100% of AML patients. Each class represents diverse biological AML subgroups, and is associated with distinct clinical presentation, likelihood of response to induction chemotherapy, risk of relapse and death over time. Secondary AML-2, emerges as the second largest class (24%), associates with high-risk disease, poor prognosis irrespective of flow Minimal Residual Disease (MRD) negativity, and derives significant benefit from transplantation. Guided by class membership we derive a 3-tier risk-stratification score that re-stratifies 26% of patients as compared to standard of care. This results in a unified framework for disease classification and risk-stratification in AML that relies on information from cytogenetics and 32 genes. Last, we develop an open-access patient-tailored clinical decision support tool.

4 October 2013 in Journal of Climate
Verified
Journal Article
Open access
EBElsa Bernard
Elsa Bernard
PNPhilippe Naveau
Philippe Naveau
MVMathieu Vrac
Mathieu Vrac
OMOlivier Mestre
Olivier Mestre
One of the main objectives of statistical climatology is to extract relevant information hidden in complex spatial–temporal climatological datasets. To identify spatial patterns, most well-known statistical techniques are based on the concept of intra- and intercluster variances (like the k-means algorithm or EOFs). As analyzing quantitative extremes like heavy rainfall has become more and more prevalent for climatologists and hydrologists during these last decades, finding spatial patterns with methods based on deviations from the mean (i.e., variances) may not be the most appropriate strategy in this context of studying such extremes. For practitioners, simple and fast clustering tools tailored for extremes have been lacking. A possible avenue to bridging this methodological gap resides in taking advantage of multivariate extreme value theory, a well-developed research field in probability, and to adapt it to the context of spatial clustering. In this paper, a novel algorithm based on this plan is proposed and studied. The approach is compared and discussed with respect to the classical k-means algorithm throughout the analysis of weekly maxima of hourly precipitation recorded in France (fall season, 92 stations, 1993–2011).

12 January 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
TGTeng Gao
Teng Gao
RPRyan Ptashkin
Ryan Ptashkin
KBKelly L. Bolton
Kelly L. Bolton
MSMaria Sirenko
Maria Sirenko
CFChristopher Fong
Christopher Fong
EPElli Papaemmanuil
Elli Papaemmanuil
Stably acquired mutations in hematopoietic cells represent substrates of selection that may lead to clonal hematopoiesis (CH), a common state in cancer patients that is associated with a heightened risk of leukemia development. Owing to technical and sample size limitations, most CH studies have characterized gene mutations or mosaic chromosomal alterations (mCAs) individually. Here we leverage peripheral blood sequencing data from 32,442 cancer patients to jointly characterize gene mutations (n = 14,789) and mCAs (n = 383) in CH. Recurrent composite genotypes resembling known genetic interactions in leukemia genomes underlie 23% of all detected autosomal alterations, indicating that these selection mechanisms are operative early in clonal evolution. CH with composite genotypes defines a patient group at high risk of leukemia progression (3-year cumulative incidence 14.6%, CI: 7–22%). Multivariable analysis identifies mCA as an independent risk factor for leukemia development (HR = 14, 95% CI: 6–33, P < 0.001). Our results suggest that mCA should be considered in conjunction with gene mutations in the surveillance of patients at risk of hematologic neoplasms.